Busulfan
Myleran · Alkylator
Conditioning-regimen TMA risk.
Ninlaro · IXA
Proteasome inhibitor · approved 2015 · 8 citations · FAERS AKI reporting ROR 1.17 (95% CI 1.05–1.30, 354 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
The first oral proteasome inhibitor, with rare reports of drug-induced thrombotic microangiopathy.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Drug-induced thrombotic microangiopathy (TMA) is a rare, case-level event for ixazomib and is not reliably quantified. In a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS, 2004-2023), proteasome inhibitors as a class were significantly associated with TMA (225 cases in 213 exposed individuals; ROR 1.71), but carfilzomib dominated the signal (58.7% of exposed individuals, 125 of 213; ROR 17.97), with bortezomib and ixazomib contributing far fewer reports. The ixazomib signal is therefore extrapolated largely from the class.Source: Deng et al., Support Care Cancer 2025 (FAERS pharmacovigilance)
Reported after weeks to months, including with cumulative exposure; class median time to TMA onset ~8 days from a triggering cycle.
Distilled from: “Variable; reported after weeks to months of therapy, including with cumulative exposure. Class median time to TMA onset ~8 days from a triggering cycle.”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.
Reversibly inhibits the chymotrypsin-like activity of the 20S proteasome (beta-5 subunit), causing accumulation of polyubiquitinated misfolded proteins, ER stress, and NF-kB-dependent apoptosis in malignant plasma cells. Used orally with lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Vasculature / Endothelium
Glomerular & peritubular capillaries
Glomerulus
Filtration barrier (podocytes + endothelium)
Class-level context for the major non-renal toxicities of the Proteasome inhibitor class.
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
Hematologic
Cytopenias, thrombosis, TMA
6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Aug 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
Reduce the NINLARO starting dose to 3 mg in patients with severe renal impairment or end-stage renal disease requiring dialysis. ( 2.4 , 8.7 )
Kidney rows of the label's dosage tables
From the NINLARO label (Aug 2026) · DailyMed
No row of this label's 3 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 28,726 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
5,294 of 28,726 reports
Reported with hospitalization
8,767 of 28,726 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 4 of the 28,726 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Ixazomib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Myleran · Alkylator
Conditioning-regimen TMA risk.
Lumoxiti · Immunotoxin (anti-CD22 PE38)
Boxed warning for capillary-leak syndrome and hemolytic-uremic syndrome / TMA.
Rasonque · RAS(ON) multi-selective inhibitor
2026 first RAS(ON) inhibitor (mutant + wild-type RAS) for pretreated metastatic pancreatic cancer; creatinine rose in 24% vs 9% on chemotherapy beside 67% diarrhea, and the label names one renal-limited TMA.
Velcade · Proteasome inhibitor
Rare TMA; reverses myeloma cast nephropathy.
Zaltrap · VEGF trap
Hypertension and proteinuria like bevacizumab.
Avastin · Anti-VEGF antibody
Proteinuria, hypertension, glomerular TMA.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Ixazomib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Ixazomib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 18 clinical records among all 22 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.